RxDoctor Payments Data

Gerardo Guarch, MD

Internal Medicine · Boynton Beach, FLNPI 1992145320

Payments from drug & device makers

$7,888in general payments, 2019–2025

Across 310 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$768
  • Lilly USA, LLC$684
  • Pfizer$612
  • Novartis$529
  • Johnson & Johnson$486
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$7,84399%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,888 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$306,828
Medicare patients
514
Services billed
3,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban175$89,405
BiktarvyBictegrav/Emtricit/Tenofov Ala13$54,684
JardianceEmpagliflozin47$34,427
FarxigaDapagliflozin Propanediol41$29,990
LinzessLinaclotide24$27,447
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$23,640
MounjaroTirzepatide21$22,288
EntrestoSacubitril/Valsartan41$21,512
MyrbetriqMirabegron54$20,484
OzempicSemaglutide13$19,397
Repatha SureclickEvolocumab22$13,993
XareltoRivaroxaban38$13,190
TrulicityDulaglutide22$12,597
Breo ElliptaFluticasone/Vilanterol12$4,728
Atorvastatin Calcium321$4,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$612$89,405175 claims
Lilly USA, LLCMounjaro, Trulicity$684$34,88443 claims
Boehringer IngelheimJardiance$44$34,42747 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$127$32,50660 claims
AstraZenecaFarxiga$1,167$29,99041 claims
AbbVieLinzess$266$27,44724 claims
NovartisEntresto$529$21,51241 claims
Novo NordiskOzempic$768$19,39713 claims
Johnson & JohnsonXarelto$486$13,19038 claims
MerckBelsomra$91$2,71915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →